Biopharmaceuticals Company Secures FDA Approval For Cutaneous T-cell Lymphoma Treatment
FDA Approval of LYMPHIR™ (Denileukin Diftitox-CXDL) for Relapsed or Refractory Cutaneous T-Cell Lymphoma.
Disclaimer: This article is intended for informational purposes only. It aims to provide a detailed overview of the recent FDA approval of LYMPHIR™ (denileukin diftitox-cxdl) by Citius Pharmaceuticals for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL). It is not meant to serve as medical advice or an end…